Trial · NCT02671266

Oxytocin Administration in BDD and OCD

NCT02671266, Phase 2, Completed, Massachusetts General Hospital; results first posted 2018-11-23

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Oxytocin Administration in BDD and OCD. Trials, record NCT02671266. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02671266

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Oxytocin Administration in BDD and OCD
NCT number: NCT02671266
Status: Completed
Phases: Phase 2
Enrollment: 41 participants, actual
Lead sponsor: Massachusetts General Hospital
Conditions: Body Dysmorphic Disorder, Obsessive-compulsive Disorder
Interventions: Oxytocin, Placebo
First posted: 2016-02-02
Last updated: 2018-11-23
Results first posted: 2018-11-23

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Emotion Recognition Questionnaire	45 minutes post nasal spray administration	This questionnaire includes 48 items for 2 conditions- a self-referent and other-referent condition. Scores are reported for each condition (self-referent or other-referent) reflecting the number of correct responses. Scores range from 0 (least accurate) to 24 (most accurate) for each condition of the questionnaire.
Secondary	Interpretation Questionnaire	At least 45 minutes post nasal spray administration	This questionnaire includes 33 ambiguous scenarios, representing 3 conditions: BDD threat scenarios, social anxiety threat scenarios, and general threat scenarios. Each item involves 3 possible thoughts that may come to mind in the scenarios which reflect positive, negative, and neutral interpretations. Participants will be asked to rate the likelihood of having each of the thoughts on a scale of 0 (very unlikely) to 4 (very likely). Total scores are reported for negative threat interpretations for each of the 3 conditions (BDD threat, social anxiety threat, general threat), with scores ranging from 0 (very unlikely) to 44 (very likely).
Secondary	Engagement Towards and Disengagement From Threat Cues in a Spatial Cueing Task	At least 45 minutes post nasal spray administration	The outcome measures are response latencies (in milliseconds) on engagement and disengagement trials for disgust, happy, and neutral cue types. Longer response latencies reflect more sustained attention.
Secondary	Amount of Initial Monetary Transfer During Trust Game	At least 45 minutes post nasal spray administration	Participants will have the decision of sending between 0 to 10 game dollars to another participant, without any expectation of monetary return. This initial investment amount will serve as a measure of trust, with a transfer of 0 game dollars indicating no trust and a transfer of 10 game dollars indicating maximum trust.

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Emotion Recognition Questionnaire	45 minutes post nasal spray administration	Data reported for BDD and healthy control participants who completed at least one drug visit. There was one patient in the oxytocin first arm who did not complete second placebo drug visit. OCD group was excluded from analyses due to difficulties with recruitment.	score on a scale	MEAN
SECONDARY	Interpretation Questionnaire	At least 45 minutes post nasal spray administration	One participant (who received oxytocin first) misunderstood the IQ so was excluded from analysis. One subject who received oxytocin first missed the second placebo drug visit. Another subject who received placebo first accidentally did not receive the Interpretation Questionnaire due to administration error. OCD group was excluded from analysis.	score on a scale	MEAN
SECONDARY	Engagement Towards and Disengagement From Threat Cues in a Spatial Cueing Task	At least 45 minutes post nasal spray administration	Data reported for BDD and HC participants who completed at least one drug visit. One HC patient in the oxytocin first arm did not complete second placebo visit. Another HC patient in the placebo first arm had missing data from the placebo visit due to administrative error. OCD group was excluded from analyses due to difficulties with recruitment.	milliseconds	MEAN
SECONDARY	Amount of Initial Monetary Transfer During Trust Game	At least 45 minutes post nasal spray administration	Sample includes BDD and healthy control participants who completed at least one drug visit. OCD group was excluded from analysis due to difficulties with recruitment.	units on a scale	MEAN

Source ClinicalTrials.gov

Results by group104

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Emotion Recognition Questionnaire	Oxytocin, Then Placebo	BDD oxytocin- self-referent	18.67	Standard Deviation 3.16	score on a scale
Emotion Recognition Questionnaire	Placebo, Then Oxytocin	BDD oxytocin- self-referent	17.00	Standard Deviation 6.41	score on a scale
Emotion Recognition Questionnaire	Oxytocin, Then Placebo	BDD placebo- self-referent	17.00	Standard Deviation 3.64	score on a scale
Emotion Recognition Questionnaire	Placebo, Then Oxytocin	BDD placebo- self-referent	16.40	Standard Deviation 6.38	score on a scale
Emotion Recognition Questionnaire	Oxytocin, Then Placebo	BDD oxytocin- other-referent	18.00	Standard Deviation 2.40	score on a scale
Emotion Recognition Questionnaire	Placebo, Then Oxytocin	BDD oxytocin- other-referent	18.30	Standard Deviation 6.77	score on a scale
Emotion Recognition Questionnaire	Oxytocin, Then Placebo	BDD placebo- other-referent	18.44	Standard Deviation 2.96	score on a scale
Emotion Recognition Questionnaire	Placebo, Then Oxytocin	BDD placebo- other-referent	16.40	Standard Deviation 6.15	score on a scale
Emotion Recognition Questionnaire	Oxytocin, Then Placebo	HC oxytocin- self-referent	15.67	Standard Deviation 6.00	score on a scale
Emotion Recognition Questionnaire	Placebo, Then Oxytocin	HC oxytocin- self-referent	17.13	Standard Deviation 3.76	score on a scale

1 to 10 of 104Source ClinicalTrials.gov

See all 104 results by group

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Oxytocin, Then Placebo	20
Overall Study	STARTED	Placebo, Then Oxytocin	21
Overall Study	BDD Participants	Oxytocin, Then Placebo	9
Overall Study	BDD Participants	Placebo, Then Oxytocin	9
Overall Study	OCD Participants	Oxytocin, Then Placebo	2
Overall Study	OCD Participants	Placebo, Then Oxytocin	3
Overall Study	Healthy Participants	Oxytocin, Then Placebo	8
Overall Study	Healthy Participants	Placebo, Then Oxytocin	8
Overall Study	COMPLETED	Oxytocin, Then Placebo	19
Overall Study	COMPLETED	Placebo, Then Oxytocin	20

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events24

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Feeling drowsy or sleepy	Nervous system disorders	Oxytocin	12	34	12
other	Feeling drowsy or sleepy	Nervous system disorders	Placebo	11	33	11
other	Feeling of calmness or euphoria	Nervous system disorders	Oxytocin	6	34	6
other	Feeling of calmness or euphoria	Nervous system disorders	Placebo	6	33	6
other	Difficulty sitting still	Nervous system disorders	Oxytocin	7	34	7
other	Difficulty sitting still	Nervous system disorders	Placebo	4	33	4
other	Headache	Nervous system disorders	Oxytocin	3	34	3
other	Headache	Nervous system disorders	Placebo	7	33	7
other	Trouble concentrating	Nervous system disorders	Oxytocin	4	34	4
other	Trouble concentrating	Nervous system disorders	Placebo	2	33	2

1 to 10 of 24Source ClinicalTrials.gov

See all 24 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Oxytocin	0	34
Total, all-cause mortality	Placebo	0	33
Total, other adverse events	Oxytocin	15	34
Total, other adverse events	Placebo	17	33
Total, serious adverse events	Oxytocin	0	34
Total, serious adverse events	Placebo	0	33

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Oxytocin vs Placebo: deaths from any cause	Trial comparisons
Oxytocin vs Placebo: serious adverse events	Trial comparisons

Tests3

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

Test	Named as	Source
Posner Cueing	Secondary outcome	ConductCognition
Scrambled Sentences Test	Secondary outcome	ConductCognition
Trust Game	Secondary outcome	ConductCognition

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02671266

GET https://conductscience.org/api/trials/v1/NCT02671266/results?page=2

API reference For AI assistants